A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2565-2570

  Kadalayil, L ^a   Benini, R ^b   Pallan, L ^c   O'Beirne, J ^d   Marelli, L ^d   Yu, D ^d   Hackshaw, A ^a   Fox, R ^c   Johnson, P ^c   Burroughs, A K ^d   Palmer, D H ^c   Meyer, T ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Embolization; Hepatocellular; Prognosis

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DOXORUBICIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HEPATOMA ARTERIAL EMBOLISATION PROGNOSTIC SCORE; HIGH RISK POPULATION; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TUMOR VOLUME;

EMBOLIZATION; HEPATOCELLULAR; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ALPHA-FETOPROTEINS; ANTIBIOTICS, ANTINEOPLASTIC; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; EMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SERUM ALBUMIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884730336     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt247     Document Type: Article

References (22)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
2. Meyer T, Kirkwood A, Roughton M et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108: 1252-1259.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
4. Raoul JL, Sangro B, Forner A et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220.
5. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
6. CLIP Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
8. Georgiades CS, Liapi E, Frangakis C et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006; 17: 1619-1624.
9. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
10. Grieco A, Pompili M, Caminiti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418.
11. Brown DB, Fundakowski CE, Lisker-Melman M et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15: 1209-1218.
12. Testa R, Testa E, Giannini E et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and model for end-stage liver disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17: 1563-1569.
13. Camma C, Di MV, Cabibbo G et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75.
14. Savastano S, Miotto D, Casarrubea G et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999; 28: 334-340.
15. O'Suilleabhain CB, Poon RT, Yong JL et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90: 325-331.
16. Llado L, Virgili J, Figueras J et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50-57.
17. Dumortier J, Chapuis F, Borson O et al. Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients. Dig Liver Dis 2006; 38: 125-133.
18. Ueno S, Tanabe G, Nuruki K et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg 2002; 9: 469-477.
19. Poon RT, Ngan H, Lo CM et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000; 73: 109-114.
20. Gillmore R, Stuart S, Kirkwood A et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-1316.
21. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res 2012; 160: 146-152.
22. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.